Management of kidney cancer patients: 2018 guidelines of the Italian Medical Oncology Association (AIOM).

Carcinoma / drug therapy Carcinoma, Renal Cell / drug therapy Humans Italy Kidney Neoplasms / drug therapy Medical Oncology / standards
AIOM Italian guidelines recommendation renal cell cancer

Journal

Tumori
ISSN: 2038-2529
Titre abrégé: Tumori
Pays: United States
ID NLM: 0111356

Informations de publication

Date de publication:
07 2019
Historique:
entrez: 3 7 2019
pubmed: 3 7 2019
medline: 10 7 2019
Statut: ppublish

Résumé

In the past two decades, the treatment landscape for patients with metastatic renal cell carcinoma has significantly changed thanks to the approval of several targeted molecular therapies (VEGF and mTOR inhibitors) and recently immune-checkpoint inhibitors. The Italian Association of Medical Oncology (AIOM) Renal Cell Cancer (RCC) Guidelines Panel has developed clinical guidelines to provide evidence-based information and recommendations to oncologists, urologists and all professionals involved in the management of patients with renal cell cancer.

Identifiants

DOI: 10.1177/0300891619853392 PMID: 31264522
pubmed: 31264522
doi: 10.1177/0300891619853392
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3-12

Auteurs

Maria Giuseppa Vitale (MG)

Medical Oncology Unit, Azienda Ospedaliera Universitaria di Modena, Modena, Italy.

Sergio Bracarda (S)

Medical Oncology Unit, Azienda Ospedaliera S.Maria, Terni, Italy.

Laura Cosmai (L)

Onco-Nephrology Outpatient Clinic, Division of Nephrology & Dialysis, San Carlo Borromeo Hospital, ASST Santi Paolo e Carlo, Milano, Italy.

Emanuele Crocetti (E)

Romagna Cancer Registry, IRCCS, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, Italy.

Giuseppe Di Lorenzo (G)

Medical Oncology Division, Department of Clinical Medicine and Surgery, University Federico II of Naples, Napoli, Italy.

Alberto Lapini (A)

Department of Urology, University of Florence, Careggi Hospital, Firenze, Italy.

Alberto Mandressi (A)

Ospedale Humanitas Mater Domini, Via Gerenzano 2, Castellanza, Varese, Italy.

Giuseppe Martorana (G)

Department of Urology, S Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy.

Cristina Masini (C)

Medical Oncology Unit, AUSL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.

Rodolfo Montironi (R)

Section of Pathological Anatomy, United Hospital, School of Medicine, Polytechnic University of the Marche Region, Ancona, Italy.

Cinzia Ortega (C)

Oncology Department, ASL CN2 Alba, Bra (CN), Italy.

Rodolfo Passalacqua (R)

Medical Oncology Department, ASST Cremona, Cremona, Italy.

Camillo Porta (C)

Department of Internal Medicine, University of Pavia and Division of Translational Oncology, IRCCS Istituti Clinici Scientifici Maugeri, Pavia, Italy.

Giuseppe Procopio (G)

Medical Oncology-Genitourinary Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano, Italy.

Pierangela Sepe (P)

Medical Oncology-Genitourinary Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano, Italy.

Luigia Romano (L)

Department of Radiology, A. Cardarelli Hospital, Napoli, Italy.

Giovanni Luigi Pappagallo (GL)

Epidemiology & Clinical Trials Office, General Hospital, Mirano (VE), Italy.

Giario Conti (G)

Urology Unit, Azienda Socio-Sanitaria Territoriale Lariana, Sant'Anna Hospital, Como, Italy.

Michele Guida (M)

Division of Medical Oncology; National Cancer Institute "Giovanni Paolo II", Bari, Italy.

Guido Martignoni (G)

Department of Diagnostic and Public Health, University of Verona, Italy.
Department of Pathology, Pederzoli Hospital, Peschiera del Garda, Italy.

Franco Nolè (F)

Medical Oncology Division of Urogenital and Head & Neck Tumours, European Institute of Oncology, Milano, Italy.

Sandro Pignata (S)

Department of Urology and Gynecology, Istituto Nazionale Tumori "Fondazione G. Pascale", Napoli, Italy.

Stefania Gori (S)

Medical Oncology, IRCCS Sacro Cuore Don Calabria Hospital, Negrar-Verona, Italy.

Giacomo Cartenì (G)

Department of Medical Oncology, Azienda Ospedaliero di Rilievo Nazionale "A. Cardarelli", Napoli, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Tumeurs épithéliales épidermoïdes et glandulaires › Carcinomes › Management of kidney cancer patients: 2018...
questionsmedicales.fr › Maladies urogénitales › Maladies urologiques › Tumeurs urologiques › Tumeurs du rein › Néphrocarcinome › Management of kidney cancer patients: 2018...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Management of kidney cancer patients: 2018...
questionsmedicales.fr › Régions géographiques › Europe › Italie › Management of kidney cancer patients: 2018...
questionsmedicales.fr › Maladies urogénitales › Maladies urologiques › Tumeurs urologiques › Tumeurs du rein › Management of kidney cancer patients: 2018...
questionsmedicales.fr › Professions de santé › Médecine › Médecine interne › Oncologie médicale › Management of kidney cancer patients: 2018...